Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Johnson, D. L.
Right arrow Articles by Jolliffe, L. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, D. L.
Right arrow Articles by Jolliffe, L. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2000) 15: 1274-1277
© 2000 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Erythropoietin mimetic peptides and the future

Dana L. Johnson and Linda K. Jolliffe

R. W. Johnson Pharmaceutical Research Institute, Raritan, NJ, USA

Introduction

The primary regulator of the growth and survival of erythroid progenitors, which mature into red blood cells, is the glycoprotein hormone erythropoietin (Epo) [1]. Epo exerts this effect by specifically interacting with a receptor present on the surface of progenitor cells which leads to receptor activation and initiation of an intracellular signal cascade. Over the last 10 years, the availability of recombinant Epo has led to its widespread use in stimulating red cell synthesis for the treatment of severe anaemia associated with acute and chronic disease [2]. In both chronic renal failure and cancer settings, severe anaemia and associated fatigue have a significant impact on the patient's quality of life. There have been a number of controlled trials in which patients receiving Epo demonstrated a significant improvement in quality of life scores and functional capacity.

While highly safe and efficacious, a desirable improvement sought for Epo . . . [Full Text of this Article]

Peptide mimics of Epo

Non-peptide mimetics

Conclusions

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Br. J. Sports. Med.Home page
N Robinson, S Giraud, C Saudan, N Baume, L Avois, P Mangin, and M Saugy
Erythropoietin and blood doping
Br. J. Sports Med., July 1, 2006; 40(suppl_1): i30 - i34.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. Naranda, R. I. Kaufman, J. Li, K. Wong, A. Boge, D. Hallen, K. Y. C. Fung, M. W. Duncan, N. Andersen, A. Goldstein, et al.
Activation of Erythropoietin Receptor through a Novel Extracellular Binding Site
Endocrinology, June 1, 2002; 143(6): 2293 - 2302.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
K.-U. Eckardt
After 15 years of success--perspectives of erythropoietin therapy
Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1745 - 1749.
[Full Text] [PDF]